Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Einstein-PE
NCT00439777Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2007
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 39
01
Overview
Phase 3, randomised, single-blind trial of rivaroxaban in pulmonary embolism (PE) and deep vein thrombosis (DVT) (2 arms), sponsored by Bayer. Primary endpoint: Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism at 12 months. Started Mar 2007; status: completed.
02
Drugs
rivaroxaban
03
Conditions
pulmonary embolism (PE)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NCT00439777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00439777.